Emergent Biosolutions financials
$6.92+0.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $234.3M | $156.1M | $148.7M | $231.1M | $140.9M | $222.2M | $194.7M | $293.8M | $254.7M | $300.4M | $276.6M | $270.5M |
| Gross profit | $137.2M | $84.1M | $63.8M | $145.2M | $74.0M | $133.7M | $76.7M | $171.2M | -$41.4M | $155.8M | $91.5M | $93.7M |
| Gross margin | 58.6% | 53.9% | 42.9% | 62.8% | 52.5% | 60.2% | 39.4% | 58.3% | −16.3% | 51.9% | 33.1% | 34.6% |
| Operating income | -$125.1M | $10.5M | -$27.9M | $76.5M | $1.6M | $49.9M | -$9.5M | $64.5M | -$203.5M | $39.8M | -$43.8M | -$242.1M |
| Net income | -$180.2M | $6.8M | -$54.6M | $51.2M | -$12.0M | $68.0M | -$31.3M | $114.8M | -$283.1M | $9.0M | -$49.5M | -$263.4M |
| Net margin | −76.9% | 4.4% | −36.7% | 22.2% | −8.5% | 30.6% | −16.1% | 39.1% | −111.2% | 3.0% | −17.9% | −97.4% |
| Diluted EPS | $-3.49 | $0.07 | $-0.93 | $0.91 | $-0.22 | $1.19 | $-0.61 | $2.06 | $-5.38 | $0.17 | $-0.95 | $-5.08 |
| EBITDA | $90.2M | $34.0M | $7.8M | $99.9M | $25.1M | $75.3M | $16.5M | $90.9M | -$147.8M | $67.7M | -$43.8M | $4.1M |
| Operating cash flow | $56.1M | -$33.8M | $77.7M | -$2.3M | $106.4M | -$11.2M | -$79.9M | $153.7M | $47.5M | -$62.6M | $32.1M | $60.0M |
| Free cash flow | $54.0M | -$36.2M | $73.8M | -$5.7M | $103.5M | -$14.8M | -$81.6M | $147.9M | $42.9M | -$73.4M | $20.7M | $47.4M |
| Diluted shares | 51.6M | 56.5M | 58.8M | 56.5M | 54.2M | 57.3M | 51.6M | 55.6M | 52.6M | 52.2M | 52.1M | 51.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $139.7M | $160.3M | $205.4M | $245.5M | $267.3M | $149.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $581.8M | $573.6M | $572.1M | $663.1M | $667.8M | $665.7M |
| Total assets | $1.12B | $1.32B | $1.32B | $1.46B | $1.42B | $1.43B |
| Total liabilities | $775.4M | $797.3M | $796.0M | $878.5M | $880.9M | $873.4M |
| Shareholders' equity | $341.4M | $523.1M | $522.6M | $582.5M | $536.2M | $552.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology